Piddybull. schreef op 18 februari 2022 12:38:
DSCRD Youngbull
Vind ik wel een vrij juiste weergave;
Staat wel op de T.A draad als inslag.
100% this is not all company specific. Just a general, around-the-board, correction. If you look around at our peers, we are not alone. Hell, the XBI at its recent lows, corrected over 50% off its highs & todays price is slightly below that percentage. Arrowhead from $94 to $45 is abouts the same 50% correction. Our tickers not doing anything the rest of the sector or risk-on stocks aren’t doing. Its the macro situation. Inflation (or worse), government, potential war, etc.. People are going to cash & there are very few willing to buy these “risk-on” tickers. So that leaves you with sellers only, at least generally speaking. Markets were over-extended finishing off 2021. As much as it sucks, we were due for a cool-off, altho 50% is quite hefty. Sad part is, the SPY may have a lot further to drop still. Could take a few months. This is where XBI “could” enter 70s & ARWR “could” see 35. Potentially may enter full on bear market in the S&P, which will also include some pretty violent rallies to the upside in the scheme of things. I think we are entering a “sell the rip” mentality vs the old “buy the dip” mentality markets used to have. Problem is, like with the new facility you mentioned, we are spending money, expanding the pipe, doing everything we can as a biotech company to remain on the up & up, but the real problem lies in the risk we carry. The phase 2 pipe (not counting orphan FCS here), the fact we don't have a drug on the market providing a solid stream of revenue, etc... Altho the company is doing great, its just not the setup people want to buy right now